Vanguard Capital Management’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
Other funds holding CAPR
Vanguard Capital Management's CAPR Position: Q3 2026 in Review
Vanguard Capital Management increased its Capricor Therapeutics (CAPR) stake by 0.25% in Q3 2026, buying an estimated $63.2K and bringing the position to 2,303,381 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2352.
Vanguard Capital Management first reported a position in CAPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $61.6M in Q1 2026. 157 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.
- Vanguard Capital Management held 2,303,381 shares of Capricor Therapeutics worth $21.8M as of Q3 2026.
- Vanguard Capital Management bought 5,707 Capricor Therapeutics shares in Q3 2026, an estimated $63.2K.
- Capricor Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2352 holding.
- Vanguard Capital Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Capricor Therapeutics position peaked at $61.6M in Q1 2026.
- 157 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.